ANTI-huTNFR1 ANTIBODY
AssigneeBaliopharm AG
InventorsRoland Kontermann, Klaus Pfizenmaier, Andreas Herrmann, Kirstin Zettlitz
Life of this patent
Estimating the term…
Abstract
The disclosure to an anti-huTNFR1 antibody of the IgG1 type, which has a modified Fc region deficient in mediating effector function, a pharmaceutical preparation comprising such antibody, and an anti-huTNFR1 antibody of the IgG1 type for use as a TNF antagonist without forming an agonistic TNFR1 signalling complex, as an alternative to treatment with an anti-TNF therapeutic.
Claims17
An anti-huTNFR1 antibody of the IgG1 type having a modified Fc region deficient in mediating effector function.
A method of treating a condition associated with expression of TNFR1 comprising the step of administering a therapeutically effective amount of an anti-huTNFR1 antibody of the IgG1 type to a patient in need thereof.
Dependencies are inferred from the claim text.